#EHA26
LightNews LightNews
myeloma-society.bsky.social
A huge "tack själv!" to #EHA26 we had a great time meeting you all and sharing details about IMS and our work. We hope to see you in #Glasgow for #IMS26!
June 14, 2026 at 12:01 PM
ash.hematology.org
Will you be at #EHA26? Be sure to stop by the ASH Booth (A4.05)!

Meet the ASH team, explore resources, and meet the Blood Journals editors. See you there! 🩸

#HemeSky
June 4, 2026 at 1:01 PM
myeloma-society.bsky.social
Hej! If you are at #EHA26, be sure to visit us at Booth A3.10 and discover everything IMS has to offer- education, research funding, advocacy efforts, career development, and more. We will have something for you!
June 11, 2026 at 7:00 AM
yalecancer.bsky.social
Saturday at the European Hematology Association (EHA) Congress, Dr. Amer Zeidan and Dr. Nikolai Podolsev presented study results during the 'Novel Treatments in #AML' session at #EHA26.
pag.virtual-meeting.org/EHA/eha2026/...
@yale-hematology.bsky.social
June 15, 2026 at 11:53 AM
yalecancer.bsky.social
Congratulations to Alexandra Boye-Doe, MD, who presented 1 of only 6 abstracts on #sicklecelldisease selected for an oral presentation at #EHA26: “A Plasma-Placental Atlas of Sickle Cell Pregnancy Reveals Endothelial, Coagulation, and Complement Dysregulation."
@yale-hematology.bsky.social
June 17, 2026 at 12:06 PM
ashclinicalnews.bsky.social
The July issue is out now! Special highlights include a feature on the outcomes of consortia-based research, recent abstracts presented as #ASCO26 and #EHA26, the intersection of #hematology and space exploration, and more. See the full issue here: https://ow.ly/hUlt50Zq89o
#HemeSky #MedSky
July 22, 2026 at 2:01 PM
ipharmaservices.bsky.social
At #EHA2026, Johnson and Johnson shows Imaavy demonstrated early and sustained hemoglobin gains in pivotal study for warm autoimmune hemolytic anemia
Track #EHA26 updates here
www.ipharmacenter.com/post/europea...
#news #media #pharmaceutical #Pharma #Oncology
European Hematology Association (EHA) 2026 Congress | iPharmaCenter
ABBVIEAbbVie shares nine‑year CLL14 results for Venetoclax regimen in previously untreated chronic lymphocytic leukemiaAbbVie has reported final nine‑year data from the Phase 3 CLL14 study, which eval...
www.ipharmacenter.com
June 12, 2026 at 5:25 PM
societyofhemonc.bsky.social
Come visit us at the SOHO booth M17 during #eha26 to learn about all of our great programs and how you can get involved with the society! Learn more at sohoonline.org
June 5, 2026 at 12:20 PM
myelomaeurope.bsky.social
“Patients shouldn’t be invited at the end to endorse decisions made without them.”

Excellent presentation by Samantha Nier on #patientpreferences and how they can help patient informed decisions on medicines.

#EHA26 #patientadvocacy
June 11, 2026 at 1:47 PM
longtail-news.bsky.social
Feed: "Clinical Trials Arena"
By: GlobalData Healthcare on Wednesday, June 17, 2026
EHA26: BMS touts positive multiple myeloma data for two pipeline candidates
BMS shared Phase III data for mezigdomide and Phase I data for a CAR-T therapy at this year’s EHA conference.
www.clinicaltrialsarena.com
June 18, 2026 at 10:34 AM
longtail-news.bsky.social
Feed: "Clinical Trials Arena"
By: GlobalData Healthcare on Tuesday, June 16, 2026
EHA26: AvenCell’s AVC-201-01 switchable allogeneic CAR T offers early validation in AML
AvenCell Therapeutics presented updated results for its CAR-T cell blood cancer therapy at EHA 2026.
www.clinicaltrialsarena.com
June 17, 2026 at 10:54 AM
longtail-news.bsky.social
Feed: "Clinical Trials Arena"
By: GlobalData Healthcare on Tuesday, June 16, 2026
EHA26: J&J’s multiple myeloma therapies impress with new data
New data for Talvey and Tecvayli was presented at the annual meeting as J&J directs its therapies in earlier-line settings.
www.clinicaltrialsarena.com
June 17, 2026 at 10:54 AM
longtail-news.bsky.social
Feed: "Clinical Trials Arena"
By: GlobalData Healthcare on Tuesday, June 16, 2026
EHA26: BTK combos in CLL/SLL showing earlier line promise
Data was presented at EHA26 by both BeOne Medicines and Eli Lilly on their CLL/SLL combinations.
www.clinicaltrialsarena.com
June 17, 2026 at 10:54 AM
longtail-news.bsky.social
Feed: "Clinical Trials Arena"
By: GlobalData Healthcare on Monday, June 15, 2026
EHA26: AstraZeneca battles Roche in untreated follicular lymphoma
AstraZeneca’s SOUNDTRACK-F1 study aims to improve on related risks seen with chemotherapy-including treatments in follicular lymphoma.
www.clinicaltrialsarena.com
June 16, 2026 at 10:32 AM
longtail-news.bsky.social
Feed: "Oncology News, Insights, Stories by OncoDaily"
Published on Sunday, June 14, 2026
Jean-Jacques Kiladjian: A Wonderful President Dinner at EHA 2026
Jean-Jacques Kiladjian: A Wonderful President Dinner at EHA 2026 / cancer, EHA 2026, EHA26, Jean-Jacques Kiladjian, OncoDaily, Oncology
oncodaily.com
June 14, 2026 at 2:04 PM
ash.hematology.org
ASH is heading to #EHA26!

Visit Booth A4.05 to explore resources and meet the Blood Journals editors. 🩸

#HemeSky
June 8, 2026 at 12:01 PM
ipharmaservices.bsky.social
At #EHA2026, AbbVie shared 9-year results from the Phase 3 CLL14 trial. In previously untreated #CLL, fixed-duration Venetoclax + obinutuzumab doubled median PFS (6.4 vs 3.2 years)
Track #EHA26 updates here
www.ipharmacenter.com/post/europea...
#news #media #pharmaceutical #Pharma #Oncology
European Hematology Association (EHA) 2026 Congress | iPharmaCenter
ABBVIEAbbVie shares nine‑year CLL14 results for Venetoclax regimen in previously untreated chronic lymphocytic leukemiaAbbVie has reported final nine‑year data from the Phase 3 CLL14 study, which eval...
www.ipharmacenter.com
June 12, 2026 at 5:23 PM
ashclinicalnews.bsky.social
#EHA26 A potential new treatment option, #bezuclastinib was found to produce favorable activity in patients with advanced systemic #mastocytosis, reducing bone marrow mast cell burden, serum tryptase levels, and KIT D816V VAF by more than 50% in most: https://ow.ly/MFJp50ZmyPw
#HemeSky #MedSky
July 15, 2026 at 3:00 PM
ashclinicalnews.bsky.social
#EHA26 In older patients with newly diagnosed, NPM1- and IDH1/2-mutated acute myeloid #leukemia #AML, a 28-day regimen of #venetoclax plus #azacitidine had greater efficacy than the standard 14-day regimen, producing CR rates of 61% vs. 33%: https://ow.ly/kg1150ZmyGF
#HemeSky #MedSky
July 13, 2026 at 5:15 PM
ashclinicalnews.bsky.social
#EHA26 In patients with #myelofibrosis, treatment with the anti-hemojuvelin antibody DISC-0974 improved #anemia and reduced #transfusion burden irrespective of JAK inhibitor use, with an overall major and minor response of 70% seen across study cohorts: https://ow.ly/A8BT50ZjI06
#HemeSky
July 3, 2026 at 3:00 PM
ashclinicalnews.bsky.social
#EHA26 In older patients with advanced-stage classic #Hodgkin #lymphoma, treatment with BrECADD using a PET-guided strategy resulted in long-term disease control with lower rates of relapse and progression, achieving a CR of 82% and 3-year PFS of 83.2%: https://ow.ly/1uf250ZjfyR
#HemeSky
July 2, 2026 at 2:20 PM
onclive.bsky.social
📢 #EHA26: Talquetamab-based combinations delivered impressive results in R/R #myeloma.

✅ Up to 72% reduction in risk of progression or death
✅ Higher CR and MRD-negative CR rates
✅ Clinically meaningful OS improvement trends

www.onclive.com/view/monumen...
MONUMENTAL-3 Data Support Talquetamab Plus Daratumumab ± Pomalidomide as a New SOC in R/R Myeloma | OncLive
Talquetamab plus daratumumab, with or without pomalidomide, significantly improved PFS and deepened responses in relapsed/refractory myeloma.
www.onclive.com
June 13, 2026 at 8:31 PM
onclive.bsky.social
🔬Early clinical data show that in vivo CAR T-cell therapy generated meaningful responses and MRD negativity in patients with relapsed/refractory multiple myeloma. 📊
Read more ➡️ www.onclive.com/view/in-vivo...
#MultipleMyeloma #CAR-T #CellTherapy #Immunotherapy #HemeOnc #Oncology #EHA26
In Vivo CAR T-Cell Therapy Drives Responses and MRD Negativity in R/R Myeloma | OncLive
The in vivo CAR T-cell therapy KLN-1010 produced deep MRD-negative responses in relapsed/refractory multiple myeloma.
www.onclive.com
June 11, 2026 at 9:08 PM